<DOC>
	<DOCNO>NCT01181245</DOCNO>
	<brief_summary>Objectives - Primary : To evaluate safety tolerability FG-3019 combination gemcitabine erlotinib - Secondary : To evaluate efficacy pharmacokinetics FG-3019 combination gemcitabine erlotinib</brief_summary>
	<brief_title>A Phase 1 Study Safety Bioactivity With FG-3019 Combination With Gemcitabine Erlotinib Subjects With Locally Advanced Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion Criteria 1 . Written inform consent 2 . Males female age â‰¥18 year old 3 . Histologically cytologically confirm adenocarcinoma pancreas 4 . Locally advanced ( Stage III ) metastatic ( Stage IV ) adenocarcinoma pancreas 5 . Spiral CT scan demonstrate least one pancreatic adenocarcinoma measurable lesion accord RECIST criterion PET scan show metabolically active lesion ( last six subject 15 mg/kg subject 25 mg/kg FG3019 dose cohort ) 6 . Women childbearing potential men must use effective contraception least 90 day follow study participation . Women childbearing potential must negative Screening serum pregnancy test . 7 . ECOG performance status score 01 8 . Life expectancy &gt; 12 week 9 . Ability adhere study visit schedule understand comply protocol requirement instruction study staff Exclusion Criteria 1 . Absolute neutrophil count ( ANC ) &lt; 500 cells/mm3 2 . Hemoglobin &lt; 10.0 g/dL 3 . Platelet count &lt; 100,000 cells/mm3 4 . Bilirubin &gt; 2.0 x upper limit normal ( ULN ) 5 . Alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 2.5 x ULN , &gt; 3.5 x ULN liver metastases present 6 . If subject diabetic , HbA1c &gt; 10 % 7 . Current pregnancy breast feeding due recent pregnancy 8 . History another malignancy past 2 year exception basal cell squamous cell carcinoma skin 9 . Previous chemotherapy gemcitabine 10 . Previous systemic antineoplastic agent ( adjuvant 5fluorouracil radiosensitizer ) 11 . Adjuvant 5fluorouracil within 28 day prior Day 1 12 . Major surgery within 28 day prior Day 1 ( stent placement allow ) 13 . Radiation therapy within 28 day prior Day 1 14 . Clinical evidence history brain metastasis 15 . Uncontrolled hypertension ( systolic blood pressure [ SBP ] &gt; 180 mmHg diastolic blood pressure [ DBP ] &gt; 105 mmHg ) 16 . New York Heart Association Class III IV congestive heart failure 17 . History allergic anaphylactic reaction human , humanize , chimeric monoclonal antibody 18 . Current clinical laboratory evidence active infection require antibiotic antiviral therapy 19 . Active major gastrointestinal bleeding 20 . Fulldose heparin therapy within 28 day prior Day 1 21 . Participation study investigational product within 42 day prior Day 1 22 . Clinically significant uncontrolled medical condition consider high risk participation investigational study likelihood subject unable comply protocol requirement complete trial ( e.g. , emphysema require supplemental oxygen , poorly control arrhythmia , psychiatric illness , Alzheimer 's disease ) 23 . Current abuse alcohol drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Pancreatic Cancer</keyword>
</DOC>